Features | Partner Sites | Information | LinkXpress
Sign In
BioConferenceLive
GLOBETECH PUBLISHING
JIB

Nonreplicating Virus Kills Leukemia in Mouse and Culture Models

By BiotechDaily International staff writers
Posted on 27 Aug 2013
Image: Electron micrograph depicts the rhabdovirus responsible for vesicular stomatitis (VS) in horses, cattle, and pigs. An inactivated rhabdovirus was used in recent studies to destroy leukemia cells (Photo couryesy of the [US] Centers for Disease Control (CDC)).
Image: Electron micrograph depicts the rhabdovirus responsible for vesicular stomatitis (VS) in horses, cattle, and pigs. An inactivated rhabdovirus was used in recent studies to destroy leukemia cells (Photo couryesy of the [US] Centers for Disease Control (CDC)).
A biopharmaceutical drug comprising nonreplicating virus particles killed leukemia cells in a mouse leukemia model and in cultures of cells taken from patients with multiple drug resistant forms of the disease.

Investigators at the University of Ottawa (Canada) speculated that high doses on a nonreplicating virus would be able to kill blood cancer cells without the dangers inherent in the use of fully competent live viruses. Toward this end they developed a method based on attenuation with UV light to produce unique high-titer bioactive yet nonreplicating rhabdovirus-derived particles (NRRPs).

This novel NRRP bio-drug was shown in a paper published in the July 12, 2013, online edition of Blood Cancer Journal to possess direct cytolytic and immunomodulatory activity against acute leukemia. In a mouse model of leukemia treated with the NRRPs 80% of the mice had markedly prolonged survival and 60% were eventually cured of the disease, while all of the untreated mice died of leukemia within 20 days.

In laboratory cultures, NRRP resistance in normal cells was mediated by intact antiviral defenses including interferon (IFN). In contrast, NRRPs administered cell cultures derived from clinical samples obtained from patients with high-burden multidrug-resistant acute myeloid leukemia killed the cancer cells.

"Our research indicated that a replicating virus might not be the safest or most effective approach for treating leukemia, so we decided to investigate whether we could make virus-derived particles that no longer replicate but still kill cancer," said senior author Dr. David Conrad, a doctor candidate in cellular and molecular medicine at the University of Ottawa. "We were delighted to see that this novel therapy was very safe at high doses, and worked extremely well in our laboratory leukemia models. We hope to test this in patients in the near future."

"Leukemia is a devastating disease that can be very difficult to treat, and new therapies are urgently needed," said Dr. Conrad. "While we are still at the early stages of this research, I think this therapy holds a lot of promise because it appears to have a potent, long-lasting effect on leukemia without the debilitating side effects of many cancer therapies used in the clinic right now. We will likely see even better results once we optimize the dose in our preparations to advance this research into human clinical trials."

Related Links:
University of Ottawa


comments powered by Disqus

Channels

Drug Discovery

view channel
Image: Molecular rendering of the crystal structure of parkin (Photo courtesy of Wikimedia Commons).

Cinnamon Feeding Blocks Development of Parkinson's Disease in Mouse Model

A team of neurological researchers has identified a molecular mechanism by which cinnamon acts to protect neurons from damage caused by Parkinson's disease (PD) in a mouse model of the syndrome.... Read more

Therapeutics

view channel
Image: This type of electronic pacemaker could become obsolete if induction of biological pacemaker cells by gene therapy proves successful (Photo courtesy of Wikimedia Commons).

Gene Therapy Induces Functional Pacemaker Cells in Pig Heart Failure Model

Cardiovascular disease researchers working with a porcine heart failure model have demonstrated the practicality of using gene therapy to replace implanted electronic pacemakers to regulate heartbeat.... Read more

Lab Technologies

view channel
Image: A one-year-old baby sits in a brain scanner, called magnetoencephalography (MEG)—a noninvasive approach to measuring brain activity. The baby listens to speech sounds such as “da” and “ta” played over headphones while researchers record her brain responses (Photo courtesy of the Institute for Learning & Brain Sciences at the University of Washington).

Brain Scanner Shows Infants’ Brains Rehearse Speech Sounds Months Before Their First Words

New research in 7- and 11-month-old infants revealed that speech sounds stimulate brain regions that coordinate and plan motor movements for speech. The new study suggests that babies’ brains begin establishing... Read more

Business

view channel

Cancer Immunotherapy Sector Predicted to Surge to USD 9 Billion Across Major Pharma Through 2022

The immunotherapy market will experience substantial growth through 2022, increasing from USD 1.1 billion in 2012 to nearly USD 9 billion in 2022 (corresponding to 23.8% annual growth) in the United Kingdom, United States, France, Germany, Italy, Spain, and Japan, according to recent market research. This notable growth... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.